Conclusion:
This case highlights the diagnostic challenges encountered in
infiltrative cardiac masses and the importance of considering rare
diseases, such as Erdheim-Chester, in the differential diagnosis.
Multimodal imaging, genetic testing, and histo-pathological examination
were instrumental in reaching an accurate diagnosis. A
multi-disciplinary approach involving multiple specialties and tailored
treatment strategies is also necessary for optimal management.
Further research and collaboration are needed to enhance our
understanding of Erdheim-Chester disease and to improve patient
outcomes..
1. Giulio C, Barbara G, Alvise B, Corrado C, Maria Grazia S, Lorenzo D.
The multifaceted clinical presentations and manifestations of
Erdheim–Chester disease: comprehensive review of the literature and of
10 new cases. Annals of the Rheumatic Diseases. 2013;72(10):1691.
2. Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M,
et al. Systemic perturbation of cytokine and chemokine networks in
Erdheim-Chester disease: a single-center series of 37 patients. Blood.
2011;117(10):2783-90.
3. Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood.
2020;135(16):1311-8.
4. Cohen-Aubart F, Emile JF, Carrat F, Helias-Rodzewicz Z, Taly V,
Charlotte F, et al. Phenotypes and survival in Erdheim-Chester disease:
Results from a 165-patient cohort. Am J Hematol. 2018;93(5):E114-e7.
5. Picarsic J, Pysher T, Zhou H, Fluchel M, Pettit T, Whitehead M, et
al. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of
the central nervous system (CNS-JXG): a revised diagnostic algorithm to
include pediatric Erdheim-Chester disease. Acta Neuropathol Commun.
2019;7(1):168.
6. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F,
et al. Dramatic efficacy of vemurafenib in both multisystemic and
refractory Erdheim-Chester disease and Langerhans cell histiocytosis
harboring the BRAF V600E mutation. Blood. 2013;121(9):1495-500.
7. Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J,
et al. Consensus guidelines for the diagnosis and clinical management of
Erdheim-Chester disease. Blood. 2014;124(4):483-92.
8. Gianfreda D, Palumbo AA, Rossi E, Buttarelli L, Manari G, Martini C,
et al. Cardiac involvement in Erdheim-Chester disease: an MRI study.
Blood. 2016;128(20):2468-71.
9. Vargas D, Richards JC, Ocazionez D, Sirajuddin A, Browne L, Restrepo
CS. Cardiothoracic manifestations of primary histiocytoses. Br J Radiol.
2016;89(1068):20160347.
10. Emile J-F, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al.
Revised classification of histiocytoses and neoplasms of the
macrophage-dendritic cell lineages. Blood. 2016;127(22):2672-81.
11. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et
al. The 2016 revision of the World Health Organization classification of
lymphoid neoplasms. Blood. 2016;127(20):2375-90.
12. Brun A-L, Touitou-Gottenberg D, Haroche J, Toledano D, Cluzel P,
Beigelman-Aubry C, et al. Erdheim-Chester disease: CT findings of
thoracic involvement. European Radiology. 2010;20(11):2579-87.
13. Egan AJM, Boardman LA, Tazelaar HD, Swensen SJ, Jett JR, Yousem SA,
et al. Erdheim-Chester Disease: Clinical, Radiologic, and
Histopathologic Findings in Five Patients with Interstitial Lung
Disease. The American Journal of Surgical Pathology. 1999;23(1).
14. Estrada-Veras JI, O’Brien KJ, Boyd LC, Dave RH, Durham B, Xi L, et
al. The clinical spectrum of Erdheim-Chester disease: an observational
cohort study. Blood Adv. 2017;1(6):357-66.
15. Haroche J, Cluzel P, Toledano D, Montalescot G, Touitou D, Grenier
PA, et al. Cardiac Involvement in Erdheim-Chester Disease. Circulation.
2009;119(25):e597-e8.
16. Haroche J, Amoura Z, Dion E, Wechsler B, Costedoat-Chalumeau N,
Cacoub P, et al. Cardiovascular involvement, an overlooked feature of
Erdheim-Chester disease: report of 6 new cases and a literature review.
Medicine (Baltimore). 2004;83(6):371-92.
17. Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A,
Davies N, et al. Mutations in SLC29A3, encoding an equilibrative
nucleoside transporter ENT3, cause a familial histiocytosis syndrome
(Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS
Genet. 2010;6(2):e1000833.
18. Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R, et al.
International expert consensus recommendations for the diagnosis and
treatment of Langerhans cell histiocytosis in adults. Blood.
2022;139(17):2601-21.
19. Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile J-F, et
al. Consensus recommendations for the diagnosis and clinical management
of Rosai-Dorfman-Destombes disease. Blood. 2018;131(26):2877-90.
20. Myra C, Sloper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RH, et
al. Treatment of Erdheim-Chester disease with cladribine: a rational
approach. Br J Ophthalmol. 2004;88(6):844-7.
21. Goyal G, Shah MV, Call TG, Litzow MR, Hogan WJ, Go RS. Clinical and
Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester
Disease. JAMA Oncol. 2017;3(9):1253-6.
22. Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn JE, Wechsler B, et al.
CNS involvement and treatment with interferon-α are independent
prognostic factors in Erdheim-Chester disease: a multicenter survival
analysis of 53 patients. Blood. 2011;117(10):2778-82.